CN114729030A - 病毒样颗粒疫苗 - Google Patents

病毒样颗粒疫苗 Download PDF

Info

Publication number
CN114729030A
CN114729030A CN202080066460.8A CN202080066460A CN114729030A CN 114729030 A CN114729030 A CN 114729030A CN 202080066460 A CN202080066460 A CN 202080066460A CN 114729030 A CN114729030 A CN 114729030A
Authority
CN
China
Prior art keywords
antigen
vlp
vaccine
protein
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080066460.8A
Other languages
English (en)
Chinese (zh)
Inventor
D.R.亨德森
T.J.埃利森
G.C.塔尔博特
Y.宋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verndari Inc
Original Assignee
Verndari Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verndari Inc filed Critical Verndari Inc
Publication of CN114729030A publication Critical patent/CN114729030A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN202080066460.8A 2019-07-30 2020-07-30 病毒样颗粒疫苗 Pending CN114729030A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962880547P 2019-07-30 2019-07-30
US62/880,547 2019-07-30
US202062990318P 2020-03-16 2020-03-16
US62/990,318 2020-03-16
PCT/US2020/044196 WO2021022008A1 (en) 2019-07-30 2020-07-30 Virus-like particle vaccines

Publications (1)

Publication Number Publication Date
CN114729030A true CN114729030A (zh) 2022-07-08

Family

ID=74228282

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080066460.8A Pending CN114729030A (zh) 2019-07-30 2020-07-30 病毒样颗粒疫苗

Country Status (7)

Country Link
US (2) US20220280633A1 (https=)
EP (1) EP4004036A4 (https=)
JP (1) JP2022543046A (https=)
CN (1) CN114729030A (https=)
AU (1) AU2020321021A1 (https=)
CA (1) CA3149390A1 (https=)
WO (1) WO2021022008A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240586T1 (hr) 2018-10-09 2024-07-19 The University Of British Columbia Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima
WO2022008973A2 (en) * 2020-07-10 2022-01-13 Covid Diagnostics Ltd. Compositions, methods, and systems for detecting immune response
CN112760420B (zh) * 2021-02-05 2023-05-26 中国科学院长春应用化学研究所 一种用于检测新冠病毒SARS-CoV-2的引物、探针和试剂盒
CN114656529B (zh) * 2021-02-08 2024-05-31 暨南大学 一种新型冠状病毒t细胞的抗原表位肽及其应用
US20220265601A1 (en) * 2021-02-10 2022-08-25 David Alan Heldreth, JR. Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
CN114957409A (zh) * 2021-02-26 2022-08-30 中国科学院上海巴斯德研究所 基于s蛋白r815位点的冠状病毒干预的方法和产品
CA3211083A1 (en) * 2021-03-04 2022-09-09 Kyle BACKMAN Compositions including sbi adjuvants and methods of use thereof
WO2022191742A1 (en) * 2021-03-11 2022-09-15 Dukhovlinov Ilya Vladimirovich A method for assessment of the cellular immune
CA3218711A1 (en) * 2021-05-13 2022-11-17 Roee Amit Methods and compositions for treatment of viral infection
WO2022261355A1 (en) * 2021-06-09 2022-12-15 Chimeron Bio Corporation Self-amplifying rna-based vlp vaccines
CN115572714A (zh) * 2021-06-21 2023-01-06 江苏泽凯生物医药技术有限公司 一种快速检测SARS-CoV-2病毒中和抗体有效性的方法
US20250082236A1 (en) * 2021-07-19 2025-03-13 Carnegie Mellon University Scalable Manufacturing of Microneedle Arrays Using Automated High-Throughput Manufacturing Systems and High-Capacity Molding
WO2023023597A1 (en) * 2021-08-18 2023-02-23 Nanored Llc Virus-like particle
IL310010A (en) * 2021-09-09 2024-03-01 Universit?T Basel Biologically produced nucleic acid for vaccine production
US20250134986A1 (en) * 2021-09-15 2025-05-01 Verndari, Inc. Stabilized lipid nanoparticle mrna compositions and uses thereof
WO2023062651A1 (en) * 2021-10-13 2023-04-20 Padmanabh Patil Harshad Virus-like particles for respiratory syncytial virus and method of preparation thereof
RU2769224C1 (ru) * 2021-12-30 2022-03-29 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Рекомбинантные вирусоподобные частицы для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2
KR20260032590A (ko) * 2023-06-29 2026-03-09 세퀴러스 인코포레이티드 재조합 바이러스 유사 입자
WO2025235418A1 (en) * 2024-05-05 2025-11-13 National Health Research Institutes Virus-like particle, preparation method thereof, and use thereof in preparing vaccine
WO2025264980A1 (en) * 2024-06-21 2025-12-26 Georgia Tech Research Corporation Ambient stabilization of mrna-hybrid lipid nanocapsules in sugar glass

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1662253A (zh) * 2002-06-20 2005-08-31 赛托斯生物技术公司 用作佐剂的包装的病毒样颗粒:制备方法与用途
US20100015218A1 (en) * 2007-02-16 2010-01-21 Vasant Jadhav Compositions and methods for potentiated activity of biologically active molecules
WO2011002522A2 (en) * 2009-07-02 2011-01-06 Medimmune, Llc Methods of making and using synthetic viruses
US20190023769A1 (en) * 2012-10-29 2019-01-24 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting pathogen infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148876A (en) * 1975-09-29 1979-04-10 Burroughs Wellcome Co. Biological preparations
JP2013542928A (ja) * 2010-09-30 2013-11-28 フランバックス ソチエタ レスポンサビリタ リミテ ビロソーム粒子の生成
ES2729967T3 (es) * 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
WO2016039620A2 (en) * 2014-09-12 2016-03-17 Bestewil Holding B.V. Respiratory syncytial virus virosomes
WO2016039619A1 (en) * 2014-09-12 2016-03-17 Bestewil Holding B.V. Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby
US10676511B2 (en) * 2015-09-17 2020-06-09 Ramot At Tel-Aviv University Ltd. Coronaviruses epitope-based vaccines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1662253A (zh) * 2002-06-20 2005-08-31 赛托斯生物技术公司 用作佐剂的包装的病毒样颗粒:制备方法与用途
US20100015218A1 (en) * 2007-02-16 2010-01-21 Vasant Jadhav Compositions and methods for potentiated activity of biologically active molecules
WO2011002522A2 (en) * 2009-07-02 2011-01-06 Medimmune, Llc Methods of making and using synthetic viruses
US20190023769A1 (en) * 2012-10-29 2019-01-24 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting pathogen infection

Also Published As

Publication number Publication date
US20220280633A1 (en) 2022-09-08
US20230000974A1 (en) 2023-01-05
JP2022543046A (ja) 2022-10-07
AU2020321021A1 (en) 2022-03-10
WO2021022008A1 (en) 2021-02-04
EP4004036A1 (en) 2022-06-01
EP4004036A4 (en) 2023-11-15
CA3149390A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
US20230000974A1 (en) Virus-like particle vaccines
Calzas et al. Innovative mucosal vaccine formulations against influenza A virus infections
CA2659275C (en) Chimeric influenza virus-like particles
US10137190B2 (en) Nucleic acid molecules encoding ferritin-hemagglutinin fusion proteins
Nian et al. Development of nasal vaccines and the associated challenges
EP2914283B1 (en) Universal influenza vaccine based on heterologous multiple m2e proteins
CN103747797B (zh) 脂质体制剂
US20120052082A1 (en) Cross-protective influenza vaccine
AU2009319979A1 (en) Improved methods for isolating enveloped virus-based VLPs free of infectious agents
CN103945863A (zh) 包含配体的vlp及其相关方法
Wang et al. Virus‐Like Particles Containing the Tetrameric Ectodomain of Influenza Matrix Protein 2 and Flagellin Induce Heterosubtypic Protection in Mice
CN110290805A (zh) 通用流感疫苗组合物
US12397050B2 (en) Universal mammalian influenza vaccine
Wu et al. Nanovaccines to combat virus‐related diseases
US10675345B2 (en) Recombinant influenza virus vaccines for influenza
HK40079920A (en) Virus-like particle vaccines
Li et al. Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity. Vaccines 2021, 9, 75
Hagenaars Towards an intranasal influenza vaccine based on whole inactivated influenza virus with N, N, N-trimethyl chitosan as adjuvant
Soema et al. Current and next generation influenza vaccines: Formulation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40079920

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220708